A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE3

Conditions

Relapsing-Remitting Multiple Sclerosis (RRMS) · Anti-CD20 Therapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Neurology Department, Hospital Gui de Chauliac, Montpellier, France
Contact: Study coordinator (Xavier Ayrignac, Medical Doctor) · x-ayrignac@chu-montpellier.fr · +33 4 67 33 74 13
Contact: Principal Investigator (Xavier Ayrignac, Medical Doctor)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis (RRMS)

Abroad (travel likely)RecruitingPHASE3

Nizhny Novgorod, Russia

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

Multiple Sclerosis · RRMS · Relapsing Remitting MS

Abroad (travel likely)RecruitingPHASE2

San Francisco, United States

Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis

Multiple Sclerosis (MS) · Relapsing-remitting Multiple Sclerosis (RRMS) · Secondary-progressive Multiple Sclerosis (SPMS)

Abroad (travel likely)Recruiting

Basel, Switzerland

RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies

Multiple Sclerosis

Abroad (travel likely)Recruiting

Milan, Italy